SecBot SecBot
SECBOTREPLAY Home › Report › SABS

SABS · SAB Biotherapeutics (SABS) announced the pricing of a public offering,…

SAB Biotherapeutics, Inc. · PRESS-RELEASE filed Mar 17, 2026 at 22:46 ET

At the news

BEARISHIMPACT 6/10

PRESS-RELEASE filed Mar 17, 2026 at 22:46 ET

SAB Biotherapeutics (SABS) announced the pricing of a public offering, selling 19.3 million shares at $3.85 and pre-funded warrants for 2.8 million shares at $3.8499, raising approximately $85 million in gross proceeds. The funds will primarily support clinical development of its lead candidate, SAB-142, for type 1 diabetes. The offering includes a 30-day underwriter option to purchase up to an additional 3.3 million shares.

  • SAB Biotherapeutics is raising approximately $85 million through a public offering of common stock and pre-funded warrants.
  • 19,324,677 shares priced at $3.85 per share; pre-funded warrants for 2,753,246 shares priced at $3.8499.
  • Underwriters have a 30-day option to purchase up to 3,311,688 additional shares.
  • Proceeds will fund development of SAB-142 through clinical trials, manufacturing, regulatory activities, and general corporate purposes.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access